Cipla is facing a major challenge with the recent launch of Lanreotide by Sun Pharma, as highlighted in a report by UBS. This new product is projected to significantly impact Cipla’s revenue, which has relied on Lanreotide for $120 million to $130 million.
*BIG NEGATIVE FOR CIPLA*
UBS SAYS SUN PHARMA LAUNCH OF LANREOTIDE CAN IMPACT CIPLA
UBS CIPLA LANREOTIDE IS VERY BIG CONTRIBUTOR AT $120-130MN , SUN TO GAIN SIGNIFICANT MARKET SHARE— RedboxGlobal India (@REDBOXINDIA) October 29, 2024
UBS highlights that the introduction of Sun Pharma’s Lanreotide could lead to a considerable loss in market share for Cipla, affecting its financial performance.
With Sun Pharma entering the market, analysts predict it will gain a significant share, putting further pressure on Cipla to maintain its position.
